ALS biomarkers for therapy development: State of the field and future directions-Reference-Cited by-同舟云学术

ALS biomarkers for therapy development: State of the field and future directions

Published:2015-12-29 Issue:2 Volume:53 Page:169-182
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle Nerve

Author:

Benatar Michael¹,Boylan Kevin²,Jeromin Andreas³,Rutkove Seward B.⁴,Berry James⁵,Atassi Nazem⁵,Bruijn Lucie⁶

Affiliation:

1. Department of Neurology; University of Miami; Miami Florida USA 33136

2. Department of Neurology; Mayo Clinic Jacksonville; Jacksonville Florida USA

3. Iron Horse Diagnostics; Scottsdale Arizona USA

4. Department of Neurology; Beth Israel Deaconess Medical Center; Boston Massachusetts USA

5. Department of Neurology; Massachusetts General Hospital; Boston Massachusetts USA

6. ALS Association; Washington DC USA

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Reference116 articles.

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework;Biomarkers Definitions Working Group;Clin Pharmacol Ther,2001

2. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry and FDA staff: qualification process for drug development Tools2014 Washington, DC CDER

3. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis;Shepheard;PLoS One,2014

4. Biomarkers and surrogate markers: an FDA perspective;Katz;NeuroRx,2004

5. The PRO-ACT database: design, initial analyses, and predictive features;Atassi;Neurology,2014

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis;eBioMedicine;2024-10

2. A comprehensive review of electrophysiological techniques in amyotrophic lateral sclerosis research;Frontiers in Cellular Neuroscience;2024-08-30

3. Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis;2024-08-13

4. The relationship of rate and pause features to the communicative participation of people living with ALS;Muscle & Nerve;2024-06-04

5. Neutrophil-to-lymphocyte ratio at diagnosis as a biomarker for survival of amyotrophic lateral sclerosis;Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration;2024-05-14